Switch theme
Sign up to access all valuation multiples
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
2010
n/a
LTM Revenue $559M
LTM EBITDA $31.4M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BGI Genomics has a last 12-month revenue (LTM) of $559M and a last 12-month EBITDA of $31.4M.
In the most recent fiscal year, BGI Genomics achieved revenue of $537M and an EBITDA of -$48.7M.
BGI Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BGI Genomics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $559M | XXX | $537M | XXX | XXX | XXX |
| Gross Profit | $251M | XXX | $223M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $31.4M | XXX | -$48.7M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -9% | XXX | XXX | XXX |
| EBIT | -$68.7M | XXX | -$56.8M | XXX | XXX | XXX |
| EBIT Margin | -12% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | -$71.9M | XXX | -$125M | XXX | XXX | XXX |
| Net Margin | -13% | XXX | -23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BGI Genomics's stock price is CNY 51 (or $7).
BGI Genomics has current market cap of CNY 21.4B (or $3.0B), and EV of CNY 18.1B (or $2.5B).
See BGI Genomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $3.0B | XXX | XXX | XXX | XXX | $-0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BGI Genomics has market cap of $3.0B and EV of $2.5B.
BGI Genomics's trades at 4.7x EV/Revenue multiple, and -51.7x EV/EBITDA.
Equity research analysts estimate BGI Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BGI Genomics has a P/E ratio of -41.3x.
See valuation multiples for BGI Genomics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 80.1x | XXX | -51.7x | XXX | XXX | XXX |
| EV/EBIT | -36.6x | XXX | -44.3x | XXX | XXX | XXX |
| EV/Gross Profit | 10.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -41.3x | XXX | -23.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -41.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBGI Genomics's last 12 month revenue growth is 11%
BGI Genomics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
BGI Genomics's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BGI Genomics's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BGI Genomics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Growth | 180% | XXX | -6% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 2% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BGI Genomics acquired XXX companies to date.
Last acquisition by BGI Genomics was XXXXXXXX, XXXXX XXXXX XXXXXX . BGI Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BGI Genomics founded? | BGI Genomics was founded in 2010. |
| Where is BGI Genomics headquartered? | BGI Genomics is headquartered in China. |
| Is BGI Genomics publicy listed? | Yes, BGI Genomics is a public company listed on SHE. |
| What is the stock symbol of BGI Genomics? | BGI Genomics trades under 300676 ticker. |
| When did BGI Genomics go public? | BGI Genomics went public in 2017. |
| Who are competitors of BGI Genomics? | Similar companies to BGI Genomics include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of BGI Genomics? | BGI Genomics's current market cap is $3.0B |
| What is the current revenue of BGI Genomics? | BGI Genomics's last 12 months revenue is $559M. |
| What is the current revenue growth of BGI Genomics? | BGI Genomics revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of BGI Genomics? | Current revenue multiple of BGI Genomics is 4.5x. |
| Is BGI Genomics profitable? | Yes, BGI Genomics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BGI Genomics? | BGI Genomics's last 12 months EBITDA is $31.4M. |
| What is BGI Genomics's EBITDA margin? | BGI Genomics's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of BGI Genomics? | Current EBITDA multiple of BGI Genomics is 80.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
